News Content
Based on the disclosed research data, the experimental treatment cycles of retatrutide have covered multiple duration dimensions. In the Phase II clinical trial, subjects received the highest dose of 12mg for **48 weeks**, achieving an average weight loss of 24.2%, with 83% of subjects achieving a weight loss of more than 15%, and no serious long-term safety signals were observed during this period. In the latest TRIUMPH-4 Phase III trial, obese patients with knee osteoarthritis who received continuous treatment for **68 weeks** achieved an average weight loss of 28.7% and significantly improved joint pain. The incidence of gastrointestinal adverse reactions was comparable to that of shorter-cycle trials, and no significant increase was observed with longer treatment duration.https://www.fiercerawsource.com/peptides/premium-high-purity-peptides-retatrutride.html
Longer-term studies are being explored in the TRIUMPH-6 trial, which has an ultra-long observation period of **125 weeks**, including an 80-week dose-induction phase and a 36-week maintenance phase, aiming to verify the long-term weight loss maintenance effect of rastaglutide. Results are expected to be released in 2028. However, researchers also point out that the longest treatment period observed in current trials only represents feasibility in the research scenario; the individual tolerance duration for ordinary patients still needs to be assessed in conjunction with metabolic indicators, adverse reactions, and other factors.
It is worth noting that rastaglutide is still in the clinical stage and has not yet received marketing authorization in any region worldwide. Clinical experts warn that rastaglutide sold through unofficial online channels carries the risk of unknown ingredients, and its safety after more than one year of use is not fully established; patients should not attempt to use it without professional guidance. The standard for future medication duration will need to be further defined by drug regulatory agencies and clinical guidelines after the complete Phase III data is released.
